XBI vs. IBB
Compare and contrast key facts about SPDR S&P Biotech ETF (XBI) and iShares Nasdaq Biotechnology ETF (IBB).
XBI and IBB are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006. IBB is a passively managed fund by iShares that tracks the performance of the NASDAQ Biotechnology Index. It was launched on Feb 5, 2001. Both XBI and IBB are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: XBI or IBB.
Performance
XBI vs. IBB - Performance Comparison
Returns By Period
In the year-to-date period, XBI achieves a 5.76% return, which is significantly higher than IBB's 0.42% return. Over the past 10 years, XBI has outperformed IBB with an annualized return of 4.95%, while IBB has yielded a comparatively lower 3.36% annualized return.
XBI
5.76%
-4.04%
5.72%
29.73%
1.44%
4.95%
IBB
0.42%
-5.49%
0.49%
15.01%
3.64%
3.36%
Key characteristics
| XBI | IBB | |
|---|---|---|
| Sharpe Ratio | 1.18 | 0.88 |
| Sortino Ratio | 1.73 | 1.30 |
| Omega Ratio | 1.21 | 1.16 |
| Calmar Ratio | 0.54 | 0.48 |
| Martin Ratio | 3.96 | 3.96 |
| Ulcer Index | 7.86% | 3.98% |
| Daily Std Dev | 26.34% | 17.91% |
| Max Drawdown | -63.89% | -62.85% |
| Current Drawdown | -45.70% | -22.04% |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
XBI vs. IBB - Expense Ratio Comparison
XBI has a 0.35% expense ratio, which is lower than IBB's 0.47% expense ratio.
Correlation
The correlation between XBI and IBB is 0.91, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Risk-Adjusted Performance
XBI vs. IBB - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Biotech ETF (XBI) and iShares Nasdaq Biotechnology ETF (IBB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
XBI vs. IBB - Dividend Comparison
XBI's dividend yield for the trailing twelve months is around 0.15%, less than IBB's 0.33% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
XBI SPDR S&P Biotech ETF | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% | 1.07% | 0.17% |
IBB iShares Nasdaq Biotechnology ETF | 0.33% | 0.26% | 0.31% | 0.21% | 0.20% | 0.17% | 0.19% | 0.30% | 0.19% | 0.03% | 0.15% | 0.03% |
Drawdowns
XBI vs. IBB - Drawdown Comparison
The maximum XBI drawdown since its inception was -63.89%, roughly equal to the maximum IBB drawdown of -62.85%. Use the drawdown chart below to compare losses from any high point for XBI and IBB. For additional features, visit the drawdowns tool.
Volatility
XBI vs. IBB - Volatility Comparison
SPDR S&P Biotech ETF (XBI) has a higher volatility of 8.40% compared to iShares Nasdaq Biotechnology ETF (IBB) at 7.19%. This indicates that XBI's price experiences larger fluctuations and is considered to be riskier than IBB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.